Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elranatamab in Relapsed/Refractory Multiple Myeloma
NCT06711705Phase 2Recruiting
- Sponsor
- University of California, San Diego
- Start
- Dec 2024
- Primary completion
- Dec 2029
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of elranatamab in multiple myeloma (MM), sponsored by University of California, San Diego. Started Dec 2024; status: recruiting.
02
Drugs
elranatamab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT06711705.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06711705.